Clinical Trials Browser

Immunotherapy × apatinib × Clear all

NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Phase 2 Completed

Gastrointestinal

Immunotherapy